Sibutramine [Meridia]: Market Withdrawal Due to Risk of Serious Cardiovascular events
October 08, 2010 – Today, we learn that Abbott Laboratories and FDA notified healthcare professionals and patients about the voluntary market withdrawal of Sibutramine [Meridia], an obesity drug, from the U.S. market because of clinical trial data indicating an increased …
Sibutramine [Meridia]: Market Withdrawal Due to Risk of Serious Cardiovascular events Read more »